Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma 2Leukemia, Biphenotypic, Acute 2Urogenital Neoplasms 1Melanoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1Colitis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

vedolizumab 1Injections 1Genetic Testing 1Gene Expression Profiling 1Gemtuzumab 1Decitabine 1Daunorubicin 1Cytarabine 1Calcineurin Inhibitors 1CPX-351 1Azacitidine 1Amplified Fragment Length Polymorphism Analysis 1Abatacept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Myelomonocytic, Acute × vedolizumab × Clear all
NCT05515029 2023-09-28

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 3 Active not recruiting
56 enrolled
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡